glp-1 agonist therapy information platforms Receptor Market Size & Share Report, 2032 Oral GLP-1-Based Therapeutics in the

Several non-invasive approaches have been developed in the past for insulin delivery [212, 213], but many of these products, particularly oral insulin products, faced challenges in clinical trials due to variable therapeutic responses owing to patient-to-patient differences in bioavailability [214-216]

Juhl CB, Prksen N, Sturis J, et al

Hathur, B

Unmet target Despite the glycaemic efficacy and related benefits of GLP-1RAs, some patients may not achieve their target HbA 1c after four to six months of use, by which time the full effects of the medication would be manifest

The critical distinction: injectable versus oral GLP-1 formulations This is the section that could prevent a serious mistake